Publication:
Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)

No Thumbnail Available

Date

2024-01-01

Authors

Pereyra-Rodriguez, Jose Juan
Poveda, José Luis
Rivero, Alvaro
Serra-Baldrich, Esther
Silvestre, Juan Francisco
Armario-Hita, José Carlos
Calleja, Miguel Angel
Carrascosa, Jose Manuel
Florez, Angeles
Herranz, Pedro

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The increased understanding of atopic dermatitis (AD) pathophysiology has shed light on the underlying immunologic mechanisms and spurred the development of novel, more precisely targeted therapies. As new agents become available, assessing their added value is advisable. Yet the value of novel health interventions sometimes remains largely unmeasured and inadequately understood. Value assessment is challenging since it involves assessing the extent to which it meets current unmet needs. Therefore, it is necessary to establish the most relevant health outcomes from different stakeholders' perspectives.

Description

MeSH Terms

Decision Making
Decision Support Techniques
Dermatitis, Atopic

DeCS Terms

Dermatitis atópica
Análisis de decisión multicriterio
Calidad de vida relacionada con la salud
Reducción del prurito
Control de la actividad de la enfermedad

CIE Terms

Keywords

Atopic dermatitis, Multi‑criteria decision analysis (MCDA), Health-related quality of life (HRQoL), Pruritus reduction, Disease activity control

Citation

Pereyra‐Rodríguez JJ, Poveda JL, Rivero A, Serra‐Baldrich E, Silvestre JF, Armario‐Hita JC et al. Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA). JEADV 2024;38:e59‐e62